robert_hesketh_hepatology_clinic

The Section of Hepatology and Gastroenterology encompasses internationally recognised research groups on liver and gut diseases. Over the last years the section has developed strong clinical and basic research activities on five main areas:

Liver disease accounts for about 2 million deaths per year in the world. We are a group of high-level and ambitious clinical and non-clinical researchers who pull their skills together to improve the health of patients with liver and gut disease."

Dr Maud Lemoine

Head of Section

1- Alcoholic and non-alcoholic liver diseases, which are a major cause of chronic liver disease and deaths in UK and globally. For the last 10 years, the Section of Hepatology and Gastroenterology is leading major trials and research activities to reduce the morbidity and mortality related to alcoholic and non-alcoholic liver disease.

2- Viral hepatitis is another major cause of death globally. The Section has developed national and international research programmes on viral hepatitis especially among neglected populations (prisoners, migrants and people living in low-and-middle-income countries). Our activities and findings are contributing to the 2030 WHO viral hepatitis elimination goals.

3- Immunology and end-stage liver disease: the section has developed expertise in the management of end-stage liver disease with a special focus on immunological mechanisms leading to increased susceptibility to infections in patients with acute on chronic liver failure. Our approach is to define novel mechanistic pathways (in vitro and in vivo) with the aim to provide insights for new targets to reverse the reported marked immune dysfunction in the studied group of patients, understand the pathogenesis of CPI-induced hepatitis and the role of immune regulation in HCC.

4- Gut microbiota: the bacterial species, which colonise the gut (microbiota), play a key role in disease and health. Our section has been working on the role of microbiota in liver and gut disease for more than 10 years. We are currently investigating the efficacy of fecal microbiota transplant in gut and liver disease.

5- Inflammatory Bowel Disease (IBD): the section supports one of the largest clinical and research activities on Crohn disease & ulcerative colitis and has been contributing to major clinical trials for many years.

Nutrition

Key studies and research groups

  • Alcohol Liver Disease group - Prof Mark Thursz
  • Non-alcoholic Liver Disease Group - Dr Peni Manoussou
  • Immunology Group - Dr Wafa Khamri
  • Gut Microbiota Group - Prof Julian Marchesi
  • Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) - Dr Maud Lemoine
  • IBD group - Prof Tim Orchard
  • Liver regeneration group - Dr Tamir Rashid
Dr Maud Lemoine

Section leadership

Head of Hepatology & Gastroenterology - Dr Maud Lemoine

Dr Maud Lemoine is a Reader and Honorary Consultant in Hepatology at St Mary’s hospital, Imperial College London, UK. She completed her medical degree and PhD in Paris, France. She also graduated in political sciences from the Institute of Political Studies in Paris. Her research activities are mainly focused on the prevention and management of viral hepatitis in resource-limited countries, mainly in Africa. 

Research group leads

Dr Peni Manoussou

Dr Peni Manoussou

Dr Peni Manoussou

Dr Tamir Rashid

Tamir Rashid

Dr Tamir Rashid
Clinical Reader in Liver Regeneration